LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)--Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...
1d
DNA-guided CRISPR flips gene editing script, opening a new path for precise diagnosis and antivirals
Ming, Professor of the Department of Chemical and Biological Engineering (CBE) at The Hong Kong University of Science and ...
Researchers at The Institute of Cancer Research have found a dual genetic test is more accurate than the traditional approach in identifying multiple myeloma patients who may be at an elevated risk of ...
VeloCD, a novel blood test, promises to forecast how illnesses will progress and the effectiveness of treatments. By ...
Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease. Liquid biopsies, which require just a ...
Researchers at Imperial College London have developed VeloCD, a method using RNA blood markers to predict disease progression and treatment response within days. The technique, adapted from RNA ...
Scientists are developing a test which could one day be used to predict how a patient's illness will progress, and even how well they will respond to treatment. The international team, led by ...
The novel Cleavage High-throughput Assay (CHiTA) developed at Penn State provides a scarless method to characterize thousands of diverse small self-cleaving RNA enzymes, called twister ribozymes, in a ...
VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...
Dr. Kayvan Zainabadi (center) is working with colleagues in Pune, India, to test the RNA-based TB diagnostic he is developing. From left: Dr. Mandar Paradkar (co-PI, pediatrician), Vidyulata Kamble, ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results